Skip to content
pharmaceutical hero image
pharmaceutical hero image

Pharmaceuticals

We act for many of the world’s largest pharmaceutical companies, giving us broad and deep insights into the key trends and risks facing companies operating in the sector.

We advise on a wide range of complex cases, working with both national and international clients on high-profile and strategic matters. We have gathered significant and relevant experience of acting for leading companies in the life sciences sector on regulatory issues and we have built a track record of running a number of multi-jurisdictional matters. We also have a strong offering advising pharmaceuticals on transactions including M&A, collaborations and fundraising. Our clients include Novartis, Pfizer, Bayer, Merck, GSK, and Johnson & Johnson among many others.

News & insights

Bird's eye view of a major intersection and suspension bridge at night

News: 10 JULY 2020

Allen & Overy advises on Immunotech Biopharm’s global offering and listing on the Hong Kong Stock Exchange

Allen & Overy has advised the joint sponsors on the global offering and listing of shares of Immunotech Biopharm Ltd (Immunotech Biopharm) on the Hong Kong Stock Exchange under Chapter 18A of the…

Read more
A drop of liquid falling into a test tube

Publications: 08 JULY 2020

Pipeline gaps and digital will drive life sciences deals

Often seen as a safe haven sector in times of crisis, the life sciences have not only been centre stage during the Covid-19 coronavirus crisis but are riding it out well.

Read more

Publications: 24 JUNE 2020

Covid-19 coronavirus: How the global life sciences sector is responding to the pandemic

Our life sciences sector team reviews the steps taken by the industry and public bodies to minimise disruption to regular business activities and to promote the development and supply of medicines and…

Read more

Publications: 24 JUNE 2020

Changes to UK merger control: public health emergencies and national security

On 21 June the UK Government announced plans to introduce a new public interest consideration to the UK merger control regime: public health emergency. It also announced a proposal to expand its…

Read more

Download our sector brochure

Life sciences A&O red molecules

An insight in to our Life Science and Healthcare sector 2020

Our global Life Sciences and Healthcare sector comprises a multi-disciplinary team. We act for companies and their investors across the industry, including in the pharmaceuticals, biotech, animal health, consumer health, med tech, and diagnostics sectors.